Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Summary

The primary objective of this study is to: -Test the activity/response rate per RECIST 1.1 criteria of anetumab ravtansine in patients with advanced pancreatic cancer who stain for mesothelin expression The secondary objectives of this study are to: * Time to Progression (TTP) defined as time from study treatment to RECIST 1.1 progression, or death (others going off study will be censored) * Toxicity in pancreatic cancer patients (at 6.5 mg/kg dose)

Timeline

Start

2017-05-11

Primary completion

2019-08-06

Completion

2019-12-11

Drugs

Indications